Eli Lilly and Company

LLYHealth carePharmaceuticals

$1,417.99

Close on Nov 4, 2026

$1.33T

What does Eli Lilly do?

Eli Lilly develops and sells medicines, mainly for diabetes and obesity (such as Mounjaro and Zepbound), cancer and immune diseases.

Revenue by region

Fiscal year 2025

United States66.7%
Europe17.7%
Rest of World9.3%
Japan3.3%
China3.0%

As reported in the company's annual report (10-K).

Stock price

Useful context, but not the main focus.

+56.4% over the past year

Drag across the chart to compare two days.Touch the chart with two fingers to compare two days.

Key financial information

What it is · Why it matters · How to read it in context.

Fiscal year 2025, ended December 2025 · U.S. dollarsClick any metric to see what it means.

$65.2B
Previous year:
$45.0B
+44.7%
Previous year:
+32.0%
+7.1%
$20.6B
Previous year:
$10.6B
31.7%
Previous year:
23.5%
13.0%
$8.97B
Positive in each of the last 5 years
$4.88B/$47.0B
Cash9%
$4.88B
Debt91%
$47.0B
As of Sep 30, 2026
46.0
Last 12 months
53.0
32.1
0.5%
Paid over the last 12 months: $6.69 per share

5-year trends

Annual figures, fiscal years 2021-2025.

Financial figures come from company filings with the U.S. Securities and Exchange Commission (SEC). Latest filing used: October 29, 2026. Stock prices are end-of-day closing prices.